Alexion Pharmaceuticals Inc (ALXN)

173.49
+0.16(+0.09%)
  • Volume:
    1,374,333
  • Bid/Ask:
    167.07/175.00
  • Day's Range:
    173.45 - 174.15

ALXN Overview

Prev. Close
173.33
Day's Range
173.45 - 174.15
Revenue
6.26B
Open
173.59
52 wk Range
99.75 - 174.15
EPS
3.05
Volume
1,374,333
Market Cap
38.35B
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
2,379,528
P/E Ratio
56.90
Beta
1.27
1-Year Change
69.18%
Shares Outstanding
221,019,230
Next Earnings Date
Jul 29, 2021
What is your sentiment on Alexion Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Alexion Pharmaceuticals Inc News

Alexion Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong SellStrong BuyStrong BuyStrong Buy
SummaryStrong SellStrong SellStrong BuyStrong BuyStrong Buy

Alexion Pharmaceuticals Inc Company Profile

Alexion Pharmaceuticals Inc Company Profile

Industry
Major Drugs
Employees
3837

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.

Read More
  • Give the anti-corona spray from marinomed-biotech some VC and invest in a pharma company which is heading to the moon:https://www.investing.com/equities/marinomed-biotech-agStudies are proving that the patented method of marinomed prevents infection with all Corona varietis including mutants. It also prevents other virus infections. They have many patents.  Do some good and get rich
    1
    • ATVI, Nio, Li and Fcel will be very good shares to buy and hold.. 30% to 60% gain gradually soon..
      1
      • Currently this should trading st about 166-167, due to the buyout. Seems like market here is off by in ballbark of 10.
        0
        • market is pricing risk of deal not going through, thats why astrazenca plummeted today
          0
        • Ok, ty, i thought as much
          0
        • Gerard Oliva Even if the deal doesn't go throught, alexion is still a compagny to buy
          0
      • Shouldnt it be trading at around 167 atm. ?
        0
        • Candy Man AZN?
          0
        • Astrazeneca
          0
        • Candy Man Ya brain farted lol, was having lunch
          0
      • still needs to go to atleast177 to represent the new marketcap of 39 bill after the sale.
        0
        • TUSK double the price very soon..Very low volume.. Easy to jump.. Don't miss it.. Good luck guys..
          1
          • why is this stock rising if it was sold
            1
            • Astra buys Alexion for a share price of $175
              0
            • only 60 is money rest AZN shares. Deal can go bust also and AZN share price is down 5pros so pris is buying price is down like 3pros. If deal goes sauer Alexion will go under original price fast and hard.
              0
          • AstraZeneca is buying this, what is next? (read article)
            0
            • Long tp 165
              0
            • they buy it at share price around 175$, shareholders get AstraZeneca shares and a premium too
              0
          • Cocrystal Pharma, Inc. (COCP), up 45%
            0
            • seems extremely undervalued and yet no takers? can anyone explain?
              1
              • if you check the historical fundamentals I agree, it seems to be very undervalued. BUT the earnings depends strongly of a very expensive drug for a rare disease and concurrents have fund a less expensive efficacious drug for the same disease.
                3
              • You were right. Its 31 aug today and the price just increased by alot.
                2
              • Waiting for low $90s, may be another shot there. It's not about what you think is undervalued, it's about what market thinks.
                1
            • what is good for week position?
              0
              • buy for ALXN?
                0
                • strong balance sheet
                  0
                  • what's going on?
                    0
                    • Nobody knows actually
                      0
                  • trash
                    3
                    • why?
                      0
                  • i think ALXN is one of the best in its industry
                    0
                    • 5
                      0
                      • Strong buy
                        0
                        • 현수 김 amazing financials and strong growth in years. Stock is one of the most undervalued on the entire market
                          0
                        • 현수 김 analysts average 12 months target price: 144$ (44% up)
                          0
                        • cool. Are you gonna sit in this comment section for 12 months?
                          1
                      • Any real thoughts on Alexion
                        0
                        • I got a deep thoughts but guess we cant upload POC here
                          0
                        • point of contacy
                          0
                        • t*
                          0
                      • Simply got into sh... company.
                        1
                        • They lost their patent in 2017 for the eculizumab or soliris, the drug which is now being tested.
                          0
                          • Will these guys launch covid-19 vaccine attempt announcement?
                            1
                            • Run away from here !
                              4
                              • idling at 114.40
                                0
                                • What happened? Down 6.6%.
                                  0
                                  • a lot competitor getting close
                                    1
                                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.